Compare LASE & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | GALT |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 261.1M |
| IPO Year | 2022 | N/A |
| Metric | LASE | GALT |
|---|---|---|
| Price | $2.23 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 405.3K | ★ 804.3K |
| Earning Date | 12-23-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,140,614.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.01 | N/A |
| 52 Week Low | $1.71 | $1.07 |
| 52 Week High | $6.77 | $7.13 |
| Indicator | LASE | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 28.84 |
| Support Level | $1.90 | $3.34 |
| Resistance Level | $2.53 | $4.35 |
| Average True Range (ATR) | 0.25 | 0.41 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 34.04 | 0.27 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasives blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, aerospace, machine manufacturing, nuclear maintenance and de-commissioning, and surface coating.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.